Bruce Booth, serving as a director at Kymera Therapeutics, Inc. (NASDAQ:KYMR), has formally disclosed a substantial reduction in his equity position through a recent Securities and Exchange Commission filing. The documentation outlines a sequence of transactions executed between June 17 and June 22, 2026, resulting in the disposition of common stock valued at approximately $45.3 million. This financial activity unfolds against a backdrop of robust market performance for Kymera, with the stock trading in close proximity to its 52-week peak of $105. At the time of reporting, the shares were priced at $99.45, marking a notable 115% appreciation over the preceding twelve months. Independent analysis from InvestingPro suggests that the current valuation may be stretched, placing Kymera among the entities identified on their list of most overvalued stocks.
On June 17, 2026, Mr. Booth initiated the transaction series by exercising vested options to acquire 11,741 shares of Kymera common stock. The exercise price was set at $20.00 per share, culminating in a total cost of $234,820. These options had reached full vesting status and were fully exercisable at the time. Immediately following the acquisition, Mr. Booth liquidated all 11,741 shares on the same day. The direct sales were executed at a weighted average price of $89.98 per share, with individual transaction prices ranging from $89.95 to $90.20. These specific sales were conducted under a Rule 10b5-1 trading plan that was established on December 16, 2025.
Concurrently, entities affiliated with Mr. Booth facilitated the indirect sale of an additional 548,804 shares of common stock between June 17 and June 22. These indirect transactions were managed by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P., operating under a separate Rule 10b5-1 trading plan adopted on December 11, 2025. Mr. Booth has formally disclaimed beneficial ownership of these indirectly held securities, except to the extent of his pecuniary interest. The aggregate impact of all reported transactions involved the sale of 560,545 shares of Kymera Therapeutics common stock, generating a total value of $45,293,293. The prices realized across these sales varied from $89.98 to $102.48.
Following the completion of these transactions, Mr. Booth holds no direct shares of Kymera Therapeutics common stock. However, his affiliated entities maintain significant indirect positions. Atlas Venture Fund X, L.P. holds 3,490,653 shares, while Atlas Venture Opportunity Fund I, L.P. retains 617,663 shares. For comprehensive insights into Kymera's valuation and financial health, detailed Pro Research Reports are available through InvestingPro, covering over 1,400 US equities.
Separately, Kymera Therapeutics has announced several key developments. The company received a $20 million milestone payment from Sanofi following the dosing of the first participant in a Phase 1 trial for KT-485, an oral IRAK4 degrader. This trial is part of a collaborative effort focusing on adult healthy volunteers and patients with hidradenitis suppurativa. Additionally, Kymera presented Phase 1 data for KT-621 at the Japanese Dermatological Association Annual Meeting, highlighting rapid absorption, high levels of STAT6 degradation, and a favorable safety profile.
Analyst sentiment remains constructive. Truist Securities reiterated a Buy rating for Kymera, maintaining a price target of $116, citing AbbVie's acquisition of Apogee as a positive sector indicator. Brookline Capital Markets raised its price target to $97, referencing promising preclinical data for KT-579 in lupus models. Furthermore, Kymera appointed Penny Carlson as Senior Vice President of Development Operations, leveraging her 20+ years of experience to oversee global clinical development.